Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress SyndromeGlobeNewsWire • 02/01/22
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime PatentGlobeNewsWire • 12/15/21
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic InnovationGlobeNewsWire • 11/22/21
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 11/10/21
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime PatentGlobeNewsWire • 10/25/21
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic ShockGlobeNewsWire • 10/14/21
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS StudyGlobeNewsWire • 10/12/21
Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech SummitGlobeNewsWire • 09/16/21
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 08/05/21
Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)GlobeNewsWire • 07/07/21
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General CounselPRNewsWire • 07/01/21
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business UpdatesPRNewsWire • 05/13/21
Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of PatentPRNewsWire • 04/19/21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business UpdatesPRNewsWire • 03/29/21